Review
Biochemistry & Molecular Biology
Daniela Miricescu, Alexandra Totan, Iulia-Ioana Stanescu-Spinu, Silviu Constantin Badoiu, Constantin Stefani, Maria Greabu
Summary: Breast cancer is a complex disease with various factors contributing to its pathogenesis. Current research is focused on the PI3K/AKT/mTOR signaling pathway and related cancer mutations. Clinical trials are also evaluating the efficacy of inhibitors targeting these signaling pathways in breast cancer treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Lubna N. Chaudhary, Julie M. Jorns, Yunguang Sun, Yee Chung Cheng, Sailaja Kamaraju, John Burfeind, Mary Beth Gonyo, Amanda L. Kong, Caitlin Patten, Tina Yen, Chandler S. Cortina, Ebony Carson, Nedra Johnson, Carmen Bergom, Shirng-Wern Tsaih, Anjishnu Banerjee, Yu Wang, Inna Chervoneva, Elizabeth Weil, Christopher R. Chitambar, Hallgeir Rui
Summary: This study observed the changes in HER1-4 protein expression after short-term neoadjuvant endocrine therapy (NET) in early-stage hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer patients. It was found that the upregulation rate of HER2 protein was 48.6%, while the downregulation rate of HER3 and HER4 proteins was 54.2%.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Biochemistry & Molecular Biology
Lea Clusan, Francois Ferriere, Gilles Flouriot, Farzad Pakdel
Summary: Breast cancer, the most common and deadliest cancer among women worldwide, is closely associated with estrogen signaling. Hormone therapy using antiestrogens is the standard treatment, but resistance inevitably occurs through various biological mechanisms. Understanding the estrogen pathway is crucial for the development of new therapies for hormone-dependent breast cancer. This mini-review summarizes the current literature on estrogen receptors in breast cancer, including their signalization, mechanisms of action, and clinical implications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Endocrinology & Metabolism
Esmael Besufikad Belachew, Dareskedar Tsehay Sewasew
Summary: The estrogen receptor is crucial in the treatment of estrogen receptor-positive breast cancer, with endocrine resistance posing a challenge. Combining drugs that target different signaling pathways and coregulatory proteins with endocrine therapy may offer a novel therapeutic approach to combat endocrine resistance.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Luca Gianni, Marco Colleoni, Giancarlo Bisagni, Mauro Mansutti, Claudio Zamagni, Lucia Del Mastro, Stefania Zambelli, Giampaolo Bianchini, Antonio Frassoldati, Ilaria Maffeis, Pinuccia Valagussa, Giuseppe Viale
Summary: This study investigates the resistance to endocrine therapy in HER2- and hormone receptor-positive breast cancer, and finds that dual HER2 blockade and palbociclib can significantly decrease Ki67 expression and achieve high objective response rate and pathological complete response. The addition of fulvestrant in the treatment regimen also shows similar therapeutic effects.
Article
Oncology
Javier A. Menendez, Adriana Papadimitropoulou, Travis Vander Steen, Elisabet Cuyas, Bharvi P. Oza-Gajera, Sara Verdura, Ingrid Espinoza, Luciano Vellon, Inderjit Mehmi, Ruth Lupu
Summary: The study highlights the critical role of fatty acid synthase (FASN) in HER2-driven tamoxifen resistance and suggests that FASN inhibition could be a novel therapeutic approach to restore tamoxifen sensitivity in endocrine-resistant breast cancer.urther research using next-generation FASN inhibitors may be therapeutically relevant in countering resistance to tamoxifen in FASN-overexpressing ER+/HER2+ breast carcinomas.
Review
Oncology
Covadonga Marti, Jose Ignacio Sanchez-Mendez
Summary: Treatment of breast cancer has evolved towards individualized management, with hormone therapy playing a key role. Neoadjuvant endocrine therapy has become an effective approach for many hormone receptor-positive breast cancers.
Review
Oncology
Ryan M. Finnegan, Ahmed M. Elshazly, Patricia Schoenlein, David A. Gewirtz
Summary: This article reviews the relationship between endocrine therapies and autophagy, exploring the different functional roles of autophagy in response to these treatments. It is found that autophagy can have cytoprotective, non-protective, cytostatic, or cytotoxic effects on tumor cells, suggesting its potential as an adjuvant therapeutic modality for endocrine therapies.
Article
Health Care Sciences & Services
Sean C. Liebscher, Lyndsey J. Kilgore, Onalisa Winblad, Nika Gloyeske, Kelsey Larson, Christa Balanoff, Lauren Nye, Anne O'Dea, Priyanka Sharma, Bruce Kimler, Qamar Khan, Jamie Wagner
Summary: This study examined the prediction of tumor shrinkage and treatment response pattern after neoadjuvant endocrine therapy (NET) for ER+, Her2- breast cancers. The results showed that Ki-67 was not a predictive factor and the response pattern varied in the tumor bed. These findings have implications for surgical planning.
Review
Oncology
Jessica Fernanda Barazetti, Tayana Shultz Jucoski, Tamyres Mingorance Carvalho, Rafaela Nasser Veiga, Ana Flavia Kohler, Jumanah Baig, Hend Al Bizri, Daniela Fiori Gradia, Sylvie Mader, Jaqueline Carvalho de Oliveira
Summary: Breast cancer is a common disease that often recurs due to resistance to tamoxifen. Understanding estrogen receptor-positive breast cancer tumors, which are the most common subtype, is crucial for more effective treatment. Non-coding RNAs play a role in tamoxifen resistance and further exploration of their mechanisms may lead to more personalized and targeted therapies.
Article
Radiology, Nuclear Medicine & Medical Imaging
Bo Ra Kwon, Sung Ui Shin, Soo-Yeon Kim, Yunhee Choi, Nariya Cho, Sun Mi Kim, Ann Yi, Bo La Yun, Mijung Jang, Su Min Ha, Su Hyun Lee, Jung Min Chang, Woo Kyung Moon
Summary: This study identified MRI features and clinical-pathologic variables associated with prolonged survival in patients with luminal breast cancer treated with neoadjuvant chemotherapy. The prediction model showed good discrimination ability and stratified prognosis into low-risk and high-risk groups. These findings contribute to the understanding and assessment of patient outcomes.
Article
Chemistry, Inorganic & Nuclear
Xiao-Meng Liu, Zhe Li, Xin-Rui He, Rui-Ping Liu, Zhong-Ying Ma, Xin Qiao, Shu-Qing Wang, Jing-Yuan Xu
Summary: The study designed and prepared a new class of multi-targeting Pt(IV) prodrugs using the FDA-approved aromatase inhibitor aminoglutethimide, with a representative compound aminoplatin 3 showing enhanced anticancer activity and lower toxicity compared to cisplatin in ER-positive MCF-7 cells.
INORGANIC CHEMISTRY FRONTIERS
(2022)
Article
Oncology
Charly Jehanno, Pascale Le Goff, Denis Habauzit, Yann Le Page, Sylvain Lecomte, Estelle Lecluze, Frederic Percevault, Stephane Avner, Raphael Metivier, Denis Michel, Gilles Flouriot
Summary: Hormone receptor positive breast cancer often develops resistance to treatment, leading to metastatic relapses. Understanding the molecular mechanisms behind this resistance is crucial. Hypoxia, a common feature of solid tumors, has been shown to promote endocrine resistance by down-regulating estrogen receptor alpha (ER alpha) expression.
Review
Pharmacology & Pharmacy
Chao Dong, Jiao Wu, Yin Chen, Jianyun Nie, Ceshi Chen
Summary: Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression in breast cancer patients. Current research is focusing on developing drugs targeting this pathway to overcome acquired resistance to standard therapies.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Cell Biology
Konstantinos E. Siatis, Efstathia Giannopoulou, Dimitra Manou, Panagiotis Sarantis, Michalis V. Karamouzis, Sofia Raftopoulou, Konstantinos Fasseas, Fatimah Mohammed Alzahrani, Haralabos P. Kalofonos, Achilleas D. Theocharis
Summary: In this study, MCF-7 cell lines resistant to fulvestrant and tamoxifen were developed, with lower proliferation capacity in 2-D cultures but retained expression of ERa and estrogen-independent proliferation. The resistant cells exhibited increased aggressiveness, with upregulated expression of EGFR, HER2, and heterodimerization of ERBB family receptors. Tyrosine kinase inhibitors showed moderate efficacy against the resistant cells, except lapatinib, which strongly reduced cell proliferation. Increased autophagy was observed in the resistant cells, but it was not associated with apoptosis. These findings provide insights for overcoming endocrine resistance by targeting underlying mechanisms.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2023)
Article
Oncology
Laura Gomez-Cuadrado, Esme Bullock, Zeanap Mabruk, Hong Zhao, Margarita Souleimanova, Pernille Rimmer Noer, Arran K. Turnbull, Claus Oxvig, Nicholas Bertos, Adam Byron, J. Michael Dixon, Morag Park, Syed Haider, Rachael Natrajan, Andrew H. Sims, Valerie G. Brunton
Summary: This study demonstrates the molecular differences in the tumor microenvironment (TME) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), identifying differences in matrix organization and growth factor signaling pathways. These differences are associated with the long-term survival outcomes in ILC.
Article
Geriatrics & Gerontology
Hailiang Mei, Jasper Boom, Salma el Abdellaoui, Kotb Abdelmohsen, Rachel Munk, Jennifer L. Martindale, Susan Kloet, Szymone M. Kielbasa, Thomas H. Sharp, Myriam Gorospe, Vered Raz
Summary: Aging-associated muscle wasting is regulated by multiple molecular processes, and aberrant mRNA processing regulation is one of the causes of muscle wasting. The poly(A)-binding protein nuclear 1 (PABPN1) plays a key role in regulating polyadenylation site (PAS) utilization. This study shows that a persistent reduction in PABPN1 levels leads to a significant loss of translation efficiency, which in turn affects protein homeostasis and contributes to aging-associated muscle atrophy.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2022)
Article
Oncology
Nadia de Gruil, Hanno Pijl, Sjoerd H. van der Burg, Judith R. Kroep
Summary: Stimulating our body's immune response through short-term fasting diets can enhance the efficacy of cancer therapy, particularly chemotherapy. This review summarizes the preclinical and clinical evidence supporting the synergistic effects of fasting diets with cancer therapy by boosting antitumor immunity. The potential mechanisms underlying these effects include enhanced tumor immunity, decreased growth signaling, and alleviation of immunosuppression. Further studies are needed to fully evaluate the benefits of combining short-term fasting with not only chemotherapy, but also immunotherapy in cancer treatment.
Article
Biochemistry & Molecular Biology
Sophie C. Hagenaars, Lennard J. M. Dekker, Bob Ravesteijn, Ronald L. P. van Vlierberghe, Fred P. H. T. M. Romijn, Linda Verhoeff, Arjen J. Witkamp, Karin E. Schenk, Kristien B. I. M. Keymeulen, Marian B. E. Menke-Pluijmers, Anneriet E. Dassen, Birgitta A. Kortmann, Jakob de Vries, Emiel J. T. Rutgers, Yuri E. M. van der Burgt, Elma Meershoek-Klein Kranenbarg, Christa M. Cobbaert, Theo M. Luider, Wilma E. Mesker, Rob A. E. M. Tollenaar
Summary: The TESTBREAST study aims to identify a novel panel of blood-based protein biomarkers for early breast cancer detection in moderate-to-high-risk women. Longitudinal measurements of protein levels in serum samples revealed a greater interpatient than intrapatient variability, and identified specific proteins associated with the disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Chingis Mustafin, Sergey Vesnin, Arran Turnbull, Michael Dixon, Alexey Goltsov, Igor Goryanin
Summary: Early diagnosis of ovarian cancer remains challenging due to lack of clear pathogenesis concept. There is a high demand for a low-cost, reliable, and safe imaging system for detecting and monitoring cancer. Medical microwave radiometry shows promising results with an accuracy of 90%.
Article
Surgery
Esmee A. Dijkstra, Per J. Nilsson, Geke A. P. Hospers, Renu R. Bahadoer, Elma Meershoek-Klein Kranenbarg, Annet G. H. Roodvoets, Hein Putter, Ake Berglund, Andres Cervantes, Rogier M. P. H. Crolla, Mathijs P. Hendriks, Jaume Capdevila, Ibrahim Edhemovic, Corrie A. M. Marijnen, Cornelis J. H. van de Velde, Bengt Glimelius, Boudewijn van Etten, Collaborative Investigators
Summary: This study analyzed the risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial. The results showed that total neoadjuvant treatment (TNT), while increasing the risk of locoregional recurrence (LRR), can still reduce disease-related treatment failure and distant metastases after 5 years.
Article
Genetics & Heredity
Anna M. Roseboom, Quinten R. Ducarmon, Bastian V. H. Hornung, Celine Harmanus, Monique J. T. Crobach, Ed J. Kuijper, Rolf H. A. M. Vossen, Susan L. Kloet, Wiep Klaas Smits
Summary: A subset of clinical isolates of Clostridioides difficile contains plasmids that can carry virulence and antimicrobial resistance genes. However, C. difficile plasmids are poorly studied. Here, we provide the complete genome sequence of a clinical isolate carrying three high-copy number plasmids from different families, advancing our understanding of C. difficile plasmid biology.
Article
Biochemistry & Molecular Biology
Jessica Roelands, Peter J. K. Kuppen, Eiman I. Ahmed, Raghvendra Mall, Tariq Masoodi, Parul Singh, Gianni Monaco, Christophe Raynaud, Noel F. C. C. de Miranda, Luigi Ferraro, Tatiana C. Carneiro-Lobo, Najeeb Syed, Arun Rawat, Amany Awad, Julie Decock, William Mifsud, Lance D. Miller, Shimaa Sherif, Mahmoud G. Mohamed, Darawan Rinchai, Marc Van den Eynde, Rosalyn W. Sayaman, Elad Ziv, Francois Bertucci, Mahir Abdulla Petkar, Stephan Lorenz, Lisa Sara Mathew, Kun Wang, Selvasankar Murugesan, Damien Chaussabel, Alexander L. Vahrmeijer, Ena Wang, Anna Ceccarelli, Khalid A. Fakhro, Gabriele Zoppoli, Alberto Ballestrero, Rob A. E. M. Tollenaar, Francesco M. Marincola, Jerome Galon, Souhaila Al Khodor, Michele Ceccarelli, Wouter Hendrickx, Davide Bedognetti
Summary: The lack of multi-omics cancer datasets with extensive follow-up information hinders the identification of accurate biomarkers of clinical outcome. In this cohort study, comprehensive genomic analyses were performed on fresh-frozen samples from 348 patients with primary colon cancer. The study revealed a gene expression signature called Immunologic Constant of Rejection that outperformed conventional prognostic molecular biomarkers. Additionally, a favorable outcome was associated with a microbiome signature driven by Ruminococcus bromii.
Article
Pharmacology & Pharmacy
Lonneke J. Graansma, Qinglian Zhai, Loes Busscher, Roberta Menafra, Redmar R. van den Berg, Susan L. Kloet, Maaike van der Lee
Summary: Genetic variations can lead to inter-individual differences in drug response. Current methods for clinical pharmacogenomic testing are limited in detecting all genetic variability in pharmacogenes. Long-read sequencing provides a valuable tool for characterizing specific gene regions and identifying novel haplotypes, potentially improving drug response prediction and therapy outcomes.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Rieneke T. Lugtenberg, Stefanie de Groot, Danny Houtsma, Vincent O. Dezentje, Annelie J. E. Vulink, Maarten J. Fischer, Johanneke E. A. Portielje, Jacobus J. M. van der Hoeven, Hans Gelderblom, Hanno Pijl, Judith R. Kroep
Summary: Docetaxel, an anti-cancer agent, can cause hypersensitivity reactions and fluid retention. High-dose corticosteroids, such as dexamethasone, have been used to reduce these adverse effects, but there is little evidence to support this practice and high doses of corticosteroids can have undesirable effects. This study aimed to evaluate the impact of reducing the dose of dexamethasone on the incidence of hypersensitivity reactions and fluid retention in patients with breast or prostate cancer.
Article
Biochemistry & Molecular Biology
Zeger Rijs, Esther Belt, Gijsbert M. M. Kalisvaart, Cornelis F. M. Sier, Peter J. K. Kuppen, Arjen H. G. Cleven, Alexander L. L. Vahrmeijer, Michiel A. J. van de Sande, Pieter B. A. A. van Driel
Summary: This study aims to evaluate the expression of eight promising biomarkers for FGS in MFS tissue samples and adjacent healthy tissue. The results show that TEM-1 is the most suitable biomarker for FGS in MFS and should be further investigated to optimize MFS treatment.
Article
Multidisciplinary Sciences
Jani de Vos, Richard P. M. A. Crooijmans, Martijn F. L. Derks, Susan L. Kloet, Bert Dibbits, Martien A. M. Groenen, Ole Madsen
Summary: This paper aims to provide a molecular and epigenetic characterization of the IPEC-J2 and SL-29 cell lines, which are of interest for the FAANG community and future biomedical research. Whole genome sequencing, gene expression, DNA methylation, chromatin accessibility, and ChIP-seq were used to investigate these cell lines. Heteroploidy of various chromosomes was observed, and higher gene expression was found in genes located on aneuploid chromosomes compared to diploid chromosomes. Regulatory complexity of gene expression, DNA methylation, and chromatin accessibility was also explored.
Article
Oncology
D. G. J. Linders, M. M. Deken, M. A. van Dam, M. N. J. M. Wasser, E. M. C. Voormolen, J. R. Kroep, G. A. M. S. van Dongen, D. Vugts, H. M. Oosterkamp, M. E. Straver, C. J. H. van de Velde, D. Cohen, P. Dibbets-Schneider, F. H. P. van Velden, L. M. Pereira Arias-Bouda, A. L. Vahrmeijer, G. J. Liefers, L. F. de Geus-Oei, D. E. Hilling
Summary: Accurate assessment of neoadjuvant therapy (NAT) response in HER2-positive breast cancer remains challenging. This study investigated the feasibility of using HER2-targeted PET/CT imaging for more accurate NAT response evaluation. The results showed that qualitative assessment of the PET/CT images was not superior to standard-of-care MRI, but quantitative assessment suggested that HER2-targeted PET/CT has potential for a more accurate response evaluation of the primary tumor after NAT in HER2-positive breast cancer.
Article
Biochemical Research Methods
Albert Blanch-Asensio, Catarina Grandela, Karina O. Brandao, Tessa de Korte, Hailiang Mei, Yavuz Ariyurek, Loukia Yiangou, Mervyn P. H. Mol, Berend J. van Meer, Susan L. Kloet, Christine L. Mummery, Richard P. Davis
Summary: This study presents a strategy for inserting large DNA payloads into specific genomic sites of mammalian cells by combining different classes of site-specific recombinases and CRISPR-Cas9-mediated homologous recombination. The method, known as STRAIGHT-IN, allows for precise site-specific replacement of genomic fragments in human induced pluripotent stem cells (hiPSCs) and enables the generation of genetically matched panels of hiPSC lines efficiently and cost effectively.
CELL REPORTS METHODS
(2022)
Article
Plant Sciences
Lejon E. M. Kralemann, Sylvia de Pater, Hexi Shen, Susan L. Kloet, Robin van Schendel, Paul J. J. Hooykaas, Marcel Tijsterman
Summary: In this study, we identified two redundant mechanisms for the integration of T-DNA 5' end into the plant genome and identified the key factors involved in these mechanisms. Furthermore, we demonstrated the roles of MRE11 and cNHEJ in the 5' end attachment and supported our findings through experimental rescue of integration defects.